Brokerages Set $38.33 Price Target for Dova Pharmaceuticals Inc (DOVA)

Dova Pharmaceuticals Inc (NASDAQ:DOVA) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Analysts have set a twelve-month consensus price target of $38.33 for the company and are expecting that the company will post ($0.47) earnings per share for the current quarter, according to Zacks. Zacks has also given Dova Pharmaceuticals an industry rank of 184 out of 265 based on the ratings given to related companies.

Several brokerages have issued reports on DOVA. BidaskClub raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday. Jefferies Group lifted their target price on Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a report on Tuesday, November 28th. Finally, Zacks Investment Research downgraded Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th.

Several institutional investors and hedge funds have recently bought and sold shares of DOVA. The Manufacturers Life Insurance Company lifted its holdings in shares of Dova Pharmaceuticals by 702.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock worth $137,000 after buying an additional 4,163 shares in the last quarter. California State Teachers Retirement System acquired a new stake in shares of Dova Pharmaceuticals during the third quarter worth $202,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Dova Pharmaceuticals during the third quarter worth $241,000. Virtus Fund Advisers LLC acquired a new stake in shares of Dova Pharmaceuticals during the fourth quarter worth $318,000. Finally, Deutsche Bank AG lifted its holdings in shares of Dova Pharmaceuticals by 139.2% during the fourth quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock worth $337,000 after buying an additional 6,836 shares in the last quarter. 26.93% of the stock is owned by institutional investors.

Shares of Dova Pharmaceuticals (NASDAQ DOVA) opened at $34.68 on Friday. Dova Pharmaceuticals has a twelve month low of $16.98 and a twelve month high of $35.00.

Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings results on Thursday, February 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.36). During the same period last year, the company posted ($0.44) EPS. equities analysts forecast that Dova Pharmaceuticals will post -1.33 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Brokerages Set $38.33 Price Target for Dova Pharmaceuticals Inc (DOVA)” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2018/02/19/brokerages-set-38-33-price-target-for-dova-pharmaceuticals-inc-dova.html.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply